

RUN DATE: 09/22/22
RUN TIME: 0027

Cayuga Medical Center LAB **LIVE**
101 Dates Drive, Ithaca, New York 14850
Summary Discharge Report - Do not Destroy

PAGE 1

Name: Blayk, Bonzeanne R DOB: 05/01/1956 Attend Dr: Adam Law MD
Acct: A00135688513 Unit: M000597460 AGE: 66 Location: LAB
Reg: 09/21/22 SEX: F Status: REG REF

Test	Day	Date	Time	Result	Reference	Units
Sodium	1	SEP 21	1205	136	(135-145)	mmol/L
Potassium	1	SEP 21	1205	4.2	(3.5-5.0)	mmol/L
Chloride	1	SEP 21	1205	102	(101-111)	mmol/L
CO2	1	SEP 21	1205	27	(22-32)	mmol/L
Anion Gap	1	SEP 21	1205	7	(2-11)	mmol/L
Glucose	1	SEP 21	1205	103 H	(70-100)	mg/dL
BUN	1	SEP 21	1205	15	(6-24)	mg/dL
Creatinine	1	SEP 21	1205	0.82	(0.51-0.95)	mg/dL
Calcium	1	SEP 21	1205	9.0	(8.6-10.3)	mg/dL
eGFR CKD-EPI	1	SEP 21	1205	78.8(A)	(>60)	

(A) Units: mL/min/1.73m²
eGFR is estimated using the 2021 CKD-EPI equation. Methods that use Cystatin C are recommended to confirm estimated GFR in adults who are at risk for or have chronic kidney disease.
According to the National Kidney Foundation, irrespective of diagnosis, the stage of the disease is based on the level of kidney function:

Stage	Description	GFR(mL/min/1.73 m ²)
1	Kidney damage with normal or decreased GFR	90
2	Kidney damage with mild decrease in GFR	60-89
3	Moderate decrease in GFR	30-59
4	Severe decrease in GFR	15-29
5	Kidney failure	<15 (or dialysis)

Testosterone 1 SEP 21 1205 26.12 (8-60) ng/dL
Estradiol 1 SEP 21 1205 318(B) pg/mL

(B) Estradiols <40 pg/mL are sent to a reference lab for low range testing.
See also (C)

(C) Postmenopausal Females < 20
Ovulating females: by day in cycle relative to LH Peak
Follicular phase - 12 10-50
 - 4 60-200
Mid-cycle - 1 120-375
Luteal phase + 2 50-155
 + 6 60-260
 + 12 15-115

** END OF REPORT **

* ML = Testing performed at Main Lab
DEPARTMENT OF PATHOLOGY, 101 DATES DRIVE, ITHACA, NEW YORK 14850
Phone # 607-274-4474 Fax #607-274-4481
Elizabeth Plocharczyk, M.D. Director New York State Permit #54017010